Cargando…

Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist

Harmine (HAR) is a beta-carboline alkaloid widely distributed in nature. It exhibits psychopharmacological effects of improving learning and memory. However, excessive dose of HAR can cause central tremor toxicity, which may be related to the glutamate system. Memantine (MEM) is a non-competitive N-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yunpeng, Li, Shuping, Wang, Youxu, Deng, Gang, Cao, Ning, Wu, Chao, Ding, Wenzheng, Wang, Yuwen, Cheng, Xuemei, Wang, Changhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479946/
https://www.ncbi.nlm.nih.gov/pubmed/30978991
http://dx.doi.org/10.3390/molecules24071430
_version_ 1783413462624370688
author Zhang, Yunpeng
Li, Shuping
Wang, Youxu
Deng, Gang
Cao, Ning
Wu, Chao
Ding, Wenzheng
Wang, Yuwen
Cheng, Xuemei
Wang, Changhong
author_facet Zhang, Yunpeng
Li, Shuping
Wang, Youxu
Deng, Gang
Cao, Ning
Wu, Chao
Ding, Wenzheng
Wang, Yuwen
Cheng, Xuemei
Wang, Changhong
author_sort Zhang, Yunpeng
collection PubMed
description Harmine (HAR) is a beta-carboline alkaloid widely distributed in nature. It exhibits psychopharmacological effects of improving learning and memory. However, excessive dose of HAR can cause central tremor toxicity, which may be related to the glutamate system. Memantine (MEM) is a non-competitive N-methyl-d-aspartate receptor antagonist. It can be used for the treatment of Alzheimer’s disease and also can block the neurotoxicity caused by glutamate. Therefore, combination of HAR and MEM would be meaningful and the pharmacokinetics investigation of HAR and MEM in combination is necessary. A ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was established and validated for the simultaneous quantitative determination of MEM, HAR and harmol (HOL), a main metabolite of HAR, in rat plasma after oral administration of HAR and MEM in combination (5.0 mg/kg of MEM combined with 20.0, 40.0, 80.0 mg/kg of HAR). The contents of HAR and HOL were determined after oral administration of HAR (20.0, 40.0 and 80.0 mg/kg), and the content of MEM was determined after oral administration of MEM (5.0 mg/kg). Blood samples were collected from each rat at 0 (pre-dose), 0.08, 0.17, 0.25, 0.33, 0.50, 0.75, 1.0, 2.0, 4.0, 8.0, 12.0 and 24.0 h after administration. The maximum peak concentration (C(max)) of MEM was obviously decreased, and the area under the plasma concentration versus time curve from zero to time t (AUC((0-t))) and mean residence time (MRT) were significantly increased after combination with HAR. The C(max) and AUC((0-t)) of HAR and its metabolite HOL were increased after combination with MEM. These findings suggested that co-administration of HAR and MEM could extend their residence time in rats, and then might increase the efficacy for treatment of Alzheimer’s disease. Therefore, this study will provide a basis for the rational combined application of HAR and MEM.
format Online
Article
Text
id pubmed-6479946
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64799462019-04-30 Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist Zhang, Yunpeng Li, Shuping Wang, Youxu Deng, Gang Cao, Ning Wu, Chao Ding, Wenzheng Wang, Yuwen Cheng, Xuemei Wang, Changhong Molecules Article Harmine (HAR) is a beta-carboline alkaloid widely distributed in nature. It exhibits psychopharmacological effects of improving learning and memory. However, excessive dose of HAR can cause central tremor toxicity, which may be related to the glutamate system. Memantine (MEM) is a non-competitive N-methyl-d-aspartate receptor antagonist. It can be used for the treatment of Alzheimer’s disease and also can block the neurotoxicity caused by glutamate. Therefore, combination of HAR and MEM would be meaningful and the pharmacokinetics investigation of HAR and MEM in combination is necessary. A ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was established and validated for the simultaneous quantitative determination of MEM, HAR and harmol (HOL), a main metabolite of HAR, in rat plasma after oral administration of HAR and MEM in combination (5.0 mg/kg of MEM combined with 20.0, 40.0, 80.0 mg/kg of HAR). The contents of HAR and HOL were determined after oral administration of HAR (20.0, 40.0 and 80.0 mg/kg), and the content of MEM was determined after oral administration of MEM (5.0 mg/kg). Blood samples were collected from each rat at 0 (pre-dose), 0.08, 0.17, 0.25, 0.33, 0.50, 0.75, 1.0, 2.0, 4.0, 8.0, 12.0 and 24.0 h after administration. The maximum peak concentration (C(max)) of MEM was obviously decreased, and the area under the plasma concentration versus time curve from zero to time t (AUC((0-t))) and mean residence time (MRT) were significantly increased after combination with HAR. The C(max) and AUC((0-t)) of HAR and its metabolite HOL were increased after combination with MEM. These findings suggested that co-administration of HAR and MEM could extend their residence time in rats, and then might increase the efficacy for treatment of Alzheimer’s disease. Therefore, this study will provide a basis for the rational combined application of HAR and MEM. MDPI 2019-04-11 /pmc/articles/PMC6479946/ /pubmed/30978991 http://dx.doi.org/10.3390/molecules24071430 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Yunpeng
Li, Shuping
Wang, Youxu
Deng, Gang
Cao, Ning
Wu, Chao
Ding, Wenzheng
Wang, Yuwen
Cheng, Xuemei
Wang, Changhong
Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
title Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
title_full Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
title_fullStr Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
title_full_unstemmed Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
title_short Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
title_sort potential pharmacokinetic drug–drug interaction between harmine, a cholinesterase inhibitor, and memantine, a non-competitive n-methyl-d-aspartate receptor antagonist
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479946/
https://www.ncbi.nlm.nih.gov/pubmed/30978991
http://dx.doi.org/10.3390/molecules24071430
work_keys_str_mv AT zhangyunpeng potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist
AT lishuping potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist
AT wangyouxu potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist
AT denggang potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist
AT caoning potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist
AT wuchao potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist
AT dingwenzheng potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist
AT wangyuwen potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist
AT chengxuemei potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist
AT wangchanghong potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist